Prostate News and Research

RSS

Elekta acquires Resonant Medical

Elekta today announced the acquisition of Resonant Medical Inc., Montreal Canada. Through this acquisition, Elekta adds exciting new solutions for image guidance as well as highly skilled R&D resources in the field of oncology imaging and motion management.

From Elekta 1 Jun 2010

IMRT avoids xerostomia, but effectiveness on controlling cancer unclear

An advanced type of cancer radiation is more successful than traditional radiation in avoiding "dry mouth" when treating head and neck cancers, but it is unknown whether the treatment is better or worse at reducing the size of tumors, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

31 May 2010

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center will present their latest research findings at the American Urological Association Annual Meeting in San Francisco, May 29 to June 3.

31 May 2010

Surgery more beneficial than drug therapy for benign prostatic hyperplasia

A 17-year-long community study looking at symptoms of enlarged prostate in over 2,000 men age 40 to 79 years suggests that surgery for benign prostatic hyperplasia (BPH) offers more relief from incontinence and obstruction symptoms than treatment from drug-based therapy, according to a new study by researchers at Mayo Clinic.

31 May 2010

Focused Ultrasound Surgery Foundation welcomes abstracts on MR-guided focused ultrasound

The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.

29 May 2010

Misonix announces sale of all rights to HIFU technology, HIFU related assets to USHIFU

Misonix, Inc., a developer of minimally invasive ultrasonic medical device technology, which is used in Europe for the ablation of tumors and worldwide for acute health conditions, today announced the sale to USHIFU, LLC of all of the rights to the High Intensity Focused Ultrasound technology previously obtained from Focus Surgery, Inc., a wholly owned subsidiary of USHIFU, together with other HIFU related assets.

29 May 2010

EDAP to showcase Ablatherm-HIFU technology and Sonolith i-sys lithotripter at AUA 2010 Annual Meeting

EDAP TMS SA, the global leader in therapeutic ultrasound, today announced it will have a strong presence in both the exhibition and the scientific program at the American Urological Association (AUA) 2010 Annual Meeting, being held May 29 – June 3, 2010 in San Francisco. EDAP will showcase its Ablatherm-HIFU technology and Sonolith i-sys lithotripter at its exhibition booth # 1938 of the Moscone Convention Center.

29 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

US HIFU acquires Sonatherm 600 medical device from Misonix

USHIFU, LLC (US HIFU), a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 (Sonablate) medical device, announces the acquisition of certain Misonix HIFU assets and European distribution rights. In addition, through its transaction with Misonix, US HIFU acquires the Sonatherm® 600 medical device, a laparoscopic HIFU system used to ablate certain soft tissues.

29 May 2010

Pancreatic cancer patients with circulating tumor cells tend to have worse outcomes: Study

Fox Chase Cancer Center investigators find that pancreatic cancer patients who have circulating tumor cells tend to have worse outcomes than patients without circulating tumor cells. Additionally, the team has uncovered evidence that not all circulating tumor cells are the same, and some may predict worse outcomes than others.

29 May 2010

New GreenLight XPS Laser System launched for treatment of BPH

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the launch and immediate availability of its new GreenLight XPS (Xcelerated Performance System) for laser treatment of benign prostatic hyperplasia or enlarged prostate.

29 May 2010

Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH

Nymox Pharmaceutical Corporation is pleased to announce the presenters and participants for the symposium and panel discussion on NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), to be held during the 2010 Annual Meeting of the American Urological Association in San Francisco at 3:00 p.m. June 1.

28 May 2010

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

28 May 2010

IMRT leads to fewer cases of xerostomia than other types of radiation: AHRQ report

28 May 2010

Amgen announces European approval of Prolia

Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

28 May 2010

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Oregon Health & Science University is partnering with the University of Oregon and Harvard Medical School to expedite basic science research into new and existing drugs and compounds that may prevent the complications associated with Fanconi anemia, an inherited condition that can lead to bone marrow failure and cancer.

28 May 2010

$Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy$

Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy

GTx, Inc. today announced that additional study results from the Phase III clinical trial evaluating toremifene 80 mg for the prevention of fractures in men with prostate cancer on androgen deprivation therapy will be presented at the 2010 Annual Meeting of the American Urological Association being held in San Francisco May 29-June 3.

27 May 2010

Dosage of statin drugs given to patients with heart disease should be monitored: Study

The type and dosage of statin drugs given to patients to treat heart disease should be proactively monitored as they can have unintended adverse effects, concludes a new study published on bmj.com.

27 May 2010

Abnormal androgen signaling in ovaries cause female infertility

Male sex hormones, such as testosterone, have well defined roles in male reproduction and prostate cancer. What may surprise many is that they also play an important role in female fertility. A new study finds that the presence and activity of male sex hormones in the ovaries helps regulate female fertility, likely by controlling follicle growth and development and preventing deterioration of follicles that contain growing eggs.

27 May 2010

New $1.4M study to develop novel computer automation techniques for reducing prep time of IMRT for cancer

Rensselaer Polytechnic Institute Professor Richard Radke is leading a new $1.4 million study to develop novel computer automation techniques that could reduce the prep time of a promising cancer-treatment technology from several hours to a few minutes.

27 May 2010

Prostate News and Research

Elekta acquires Resonant Medical

IMRT avoids xerostomia, but effectiveness on controlling cancer unclear

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

Surgery more beneficial than drug therapy for benign prostatic hyperplasia

Focused Ultrasound Surgery Foundation welcomes abstracts on MR-guided focused ultrasound

Misonix announces sale of all rights to HIFU technology, HIFU related assets to USHIFU

EDAP to showcase Ablatherm-HIFU technology and Sonolith i-sys lithotripter at AUA 2010 Annual Meeting

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

US HIFU acquires Sonatherm 600 medical device from Misonix

Pancreatic cancer patients with circulating tumor cells tend to have worse outcomes: Study

New GreenLight XPS Laser System launched for treatment of BPH

Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

IMRT leads to fewer cases of xerostomia than other types of radiation: AHRQ report

Amgen announces European approval of Prolia

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy

Dosage of statin drugs given to patients with heart disease should be monitored: Study

Abnormal androgen signaling in ovaries cause female infertility

New $1.4M study to develop novel computer automation techniques for reducing prep time of IMRT for cancer

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News